Terms ending in 2028
Every in-force patent on Celeniv Pte. Ltd.'s record whose computed term ends in 2028, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 8,916,146 | Treatment of Inflammatory Diseases Using Placental Stem Cells In force · High confidence | Celeniv Pte. Ltd. | In force | High confidence | |
| US 10,494,607 | CD34+,CD45- Placental Stem Cell-Enriched Cell Populations In force · High confidence | Celeniv Pte. Ltd. | In force | High confidence | |
| US 9,339,520 | Methods and Compositions for Treatment of Bone Defects with Placental Cell Populations In force · High confidence | Celeniv Pte. Ltd. | In force | High confidence | |
| US 9,216,200 | Tumor Suppression Using Human Placental Perfusate and Human Placenta-Derived Intermediate Natural Killer Cells In force · High confidence | Celeniv Pte. Ltd. | In force | High confidence | |
| US 9,725,694 | Composition for Collecting and Preserving Placental Stem Cells and Methods of Using the Composition In force · High confidence | Celeniv Pte. Ltd. | In force | High confidence |
5 of 5 patents shown. Soonest term end first, then patent number.
Updated Nov 20, 2026 · includes USPTO assignment data published Nov 19, 2026, status data published Nov 20, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.